skip to main content

PCI LS-SCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerPCI LS-SCLCSCE Medical Oncology

A patient with limited-stage SCLC, WHO performance status 2, has no progression after first-line chemoradiotherapy and has no brain metastasis. Which cranial strategy follows NICE NG122?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Offer prophylactic cranial irradiation 25 Gy in 10 fractions

NG122 recommends offering PCI 25 Gy in 10 fractions to people with limited-stage SCLC, WHO performance status 0–2, whose disease has not progressed after first-line treatment. It does not require a complete response. The uncertainty around MRI surveillance is greater in extensive-stage disease and does not erase this UK limited-stage recommendation.

Reference: NICE NG122: lung cancer management. https://www.nice.org.uk/guidance/ng122/chapter/Management